University of Poitiers
Also known as: Centre Hospitalier Universitaire (CHU) de Poitiers | Centre Hospitalier Universitaire Poitiers | CHU 86021 Poitiers cedex | CHU de Poitiers FRANCE | CHU de Poitiers-POITIERS | CHU Poitiers | CHU POITIERS | CHU Poitiers, France | CHU POITIERS France | Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE | Department of Oncology Hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE | Dpt of Ophthalmology, University Hospital of Poitiers, France | Poitiers (FR), University College Hospital | Poitiers hospital | Poitiers Hospital University | Poitiers University | Poitiers University Hospital | Poitiers University Hospital, POITIERS, 86021, FRANCE | University College Hospital, Poitiers | University Hospital of Poitiers | University Hospital of Poitiers, france | University of Poitiers
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1998Last known activity
Jun 30, 2025
Timeline
1430s
- Jun 1, 1431
University of Poitiers— Founded
Drugs by trial phase (115 distinct, 87 trials)
Phase 4 (14 own, 0 via acquisition)
Phase 3 (46 own, 0 via acquisition)
Phase 2 (43 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Other trials (6 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Adenocarcinoma
- Anxiety Disorders
- Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
- Bacterial Infections
- Brain Death
- Brain Injuries
- Brain Injuries, Traumatic
- Brugada Syndrome
- Carcinoma
- Carcinoma, Merkel Cell
- Choroidal Neovascularization
- Colonic Neoplasms
- Colorectal Neoplasms
- Critical Illness
- Cystic Fibrosis
- Diabetic Retinopathy
- Disease
- Disease Progression
- Edema
- Fibrosis
- Head and Neck Neoplasms
- Hemorrhage
- Hyperkalemia
- Hypoxia
- Infections
- Kidney Diseases
- Kidney Failure, Chronic
- Leiomyoma
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Lung Diseases
- Lung Diseases, Obstructive
- Lymphoma
- Lymphoma, Non-Hodgkin
- Macular Edema
- Multiple Myeloma
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Myofibroma
- Neoplasms, Plasma Cell
- Neovascularization, Pathologic
- Obesity, Morbid
- Pain
- Paralysis
- Parkinson Disease
- Pneumonia
- Pneumonia, Ventilator-Associated
- Prostatic Neoplasms
- Psoriasis
- Pulmonary Aspergillosis
- Pulmonary Disease, Chronic Obstructive
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Retinal Diseases
- Retinal Neoplasms
- Retinoblastoma
- Subarachnoid Hemorrhage
- Surgical Wound Infection
- Syndrome
- Tourette Syndrome
- Vocal Cord Paralysis
- Wounds and Injuries
Recent trials (50)
- NCT06892951CollaboratorPhase 1/Phase 2Jun 30, 2025
- NCT06585020CollaboratorPhase 2Oct 31, 2024
- NCT06642844CollaboratorPhase 3Oct 30, 2024
- NCT06130423Lead sponsorN/AJan 10, 2024
- NCT05755789Lead sponsorPhase 3Jun 22, 2023
- NCT05589220Lead sponsorN/ANov 1, 2022
- NCT04698057Lead sponsorPhase 3Mar 1, 2022
- NCT04779255Lead sponsorN/AJul 28, 2021
- NCT04751877Lead sponsorPhase 3Jul 17, 2021
- NCT04788810Lead sponsorN/AMar 1, 2021
- NCT04460235Lead sponsorPhase 4Jan 29, 2021
- NCT04354103Lead sponsorPhase 2Jun 30, 2020
- NCT04391660Lead sponsorPhase 4Jun 1, 2020
- NCT04371965Lead sponsorPhase 2May 1, 2020
- NCT04362527Overall official - principal investigatorPhase 3Apr 30, 2020
Details
- Founded
- Poitiers, FR Jun 1, 1431
- Last known activity
- Jun 30, 2025